Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration
of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor …

Tumors represent a hostile environment for the effector cells of cancer immunosurveillance.
Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly …

Oncolytic viruses (OVs) have been widely used as anticancer therapeutics because of their
systemic immune responses during viral replication. However, the low enrichment of OVs …

Cancer immunotherapy can induce durable antitumor responses. However, many patients
poorly respond to such therapies. Here we describe a generic antitumor therapy that is …

Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the
immune response. While for decades the field isolated lytic capability and viral spread to …

Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune
responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic …

Biological therapy is considered an alternative treatment capable of eliciting the same
effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in …

Oncolytic virus (OV) therapy is an emerging approach with the potential to redefine treatment
options across a range of cancer indications and in patients who remain resistant to existing …

Colorectal cancer (CRC) is known to be resistant to immunotherapy. In our phase-I clinical
trial, one patient achieved a 313-day prolonged response during the combined treatment of …

Highlights•Oncolytic viruses have shown significant promise in glioma management.•Food
and Drug Administration (FDA) approval for oncolytic virus in melanoma has accelerated …